396 related articles for article (PubMed ID: 16217287)
1. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
3. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
4. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
5. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
6. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
8. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
9. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
10. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
11. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
Humphrey PA; Keetch DW; Smith DS; Shepherd DL; Catalona WJ
J Urol; 1996 Mar; 155(3):816-20. PubMed ID: 8583583
[TBL] [Abstract][Full Text] [Related]
12. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers].
Villers A; Soulié M; Haillot O; Boccon-Gibod L
Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329
[TBL] [Abstract][Full Text] [Related]
13. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
[TBL] [Abstract][Full Text] [Related]
14. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
Gilliland F; Becker TM; Smith A; Key CR; Samet JM
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
[TBL] [Abstract][Full Text] [Related]
15. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
17. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
19. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
Antenor JA; Han M; Roehl KA; Nadler RB; Catalona WJ
J Urol; 2004 Jul; 172(1):90-3. PubMed ID: 15201744
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]